ANI Pharmaceuticals, Inc. (ANIP)
USD 68.72
(0.88%)
USD 68.72
(0.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 109.32 Million USD | 242.61% |
| 2022 | 48.06 Million USD | 116.47% |
| 2021 | -1.68 Million USD | -48.41% |
| 2020 | 29.06 Million USD | -53.01% |
| 2019 | 60.73 Million USD | -11.29% |
| 2018 | 69.1 Million USD | 19.81% |
| 2017 | 57.16 Million USD | 16.69% |
| 2016 | 56.3 Million USD | 23.69% |
| 2015 | 39.64 Million USD | 64.87% |
| 2014 | 24.04 Million USD | 1311.86% |
| 2013 | 7.5 Million USD | 107.44% |
| 2012 | -27.23 Million USD | 54.89% |
| 2011 | -50.77 Million USD | -22.26% |
| 2010 | -45.34 Million USD | -41.63% |
| 2009 | -47.24 Million USD | -63.16% |
| 2008 | -17.38 Million USD | -109.21% |
| 2007 | -7.49 Million USD | -285.35% |
| 2006 | 3.55 Million USD | 154.84% |
| 2005 | -9.55 Million USD | 30.53% |
| 2004 | -11.91 Million USD | -104.34% |
| 2003 | -5.95 Million USD | -60.09% |
| 2002 | -3.71 Million USD | -39.0% |
| 2001 | -2.67 Million USD | 24.47% |
| 2000 | -3.31 Million USD | -133.96% |
| 1999 | -1.51 Million USD | 39.91% |
| 1998 | -2.51 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 29.74 Million USD | 24.41% |
| 2024 Q2 | 20.22 Million USD | -20.23% |
| 2023 FY | - USD | 242.61% |
| 2023 Q1 | 26.65 Million USD | 37.0% |
| 2023 Q2 | 28.07 Million USD | 5.34% |
| 2023 Q3 | 30.56 Million USD | 8.85% |
| 2023 Q4 | 23.9 Million USD | -21.78% |
| 2022 Q4 | 19.45 Million USD | 35.01% |
| 2022 FY | - USD | 116.47% |
| 2022 Q3 | 14.4 Million USD | 350.0% |
| 2022 Q1 | -3.97 Million USD | 58.19% |
| 2022 Q2 | 3.2 Million USD | 180.57% |
| 2021 Q1 | 13.42 Million USD | 16.59% |
| 2021 Q2 | 4.1 Million USD | -69.44% |
| 2021 FY | - USD | -48.41% |
| 2021 Q3 | 6.71 Million USD | 63.57% |
| 2021 Q4 | -9.5 Million USD | -241.59% |
| 2020 Q2 | -225 Thousand USD | -106.71% |
| 2020 Q1 | 3.35 Million USD | -31.01% |
| 2020 Q3 | 13.93 Million USD | 6291.56% |
| 2020 FY | - USD | -53.01% |
| 2020 Q4 | 11.51 Million USD | -17.33% |
| 2019 FY | - USD | -11.29% |
| 2019 Q4 | 4.85 Million USD | -71.03% |
| 2019 Q2 | 18.81 Million USD | -7.68% |
| 2019 Q3 | 16.76 Million USD | -10.86% |
| 2019 Q1 | 20.37 Million USD | 3.68% |
| 2018 Q1 | 14.67 Million USD | 1.9% |
| 2018 Q3 | 18.68 Million USD | 20.17% |
| 2018 Q2 | 15.54 Million USD | 5.96% |
| 2018 FY | - USD | 19.81% |
| 2018 Q4 | 19.65 Million USD | 5.19% |
| 2017 Q4 | 14.39 Million USD | -12.87% |
| 2017 FY | - USD | 16.69% |
| 2017 Q3 | 16.52 Million USD | 17.4% |
| 2017 Q2 | 14.07 Million USD | 24.42% |
| 2017 Q1 | 11.31 Million USD | 60.08% |
| 2016 Q2 | 11.13 Million USD | 8.38% |
| 2016 Q1 | 10.27 Million USD | 22.64% |
| 2016 FY | - USD | 23.69% |
| 2016 Q4 | 7.06 Million USD | -49.03% |
| 2016 Q3 | 13.86 Million USD | 24.49% |
| 2015 Q1 | 10.96 Million USD | -9.72% |
| 2015 Q2 | 9.82 Million USD | -10.34% |
| 2015 FY | - USD | 64.87% |
| 2015 Q3 | 10.49 Million USD | 6.81% |
| 2015 Q4 | 8.38 Million USD | -20.18% |
| 2014 Q3 | 9.38 Million USD | 635.12% |
| 2014 Q2 | -1.75 Million USD | -141.5% |
| 2014 Q4 | 12.14 Million USD | 29.36% |
| 2014 Q1 | 4.22 Million USD | 7.61% |
| 2014 FY | - USD | 1311.86% |
| 2013 Q1 | -2.77 Million USD | 19.83% |
| 2013 FY | - USD | 107.44% |
| 2013 Q4 | 3.92 Million USD | 193.23% |
| 2013 Q3 | 1.33 Million USD | 132.98% |
| 2013 Q2 | -4.06 Million USD | -46.43% |
| 2012 Q4 | -3.46 Million USD | 34.8% |
| 2012 Q2 | -7.25 Million USD | -5.15% |
| 2012 Q1 | -6.89 Million USD | 32.8% |
| 2012 FY | - USD | 54.89% |
| 2012 Q3 | -5.3 Million USD | 26.84% |
| 2011 Q3 | -13.45 Million USD | -19.26% |
| 2011 Q1 | -15.76 Million USD | -19.49% |
| 2011 FY | - USD | -22.26% |
| 2011 Q4 | -10.26 Million USD | 23.71% |
| 2011 Q2 | -11.28 Million USD | 28.41% |
| 2010 Q2 | -9.81 Million USD | -30.79% |
| 2010 FY | - USD | -41.63% |
| 2010 Q1 | -7.5 Million USD | 47.75% |
| 2010 Q4 | -13.19 Million USD | -19.74% |
| 2010 Q3 | -11.01 Million USD | -12.23% |
| 2009 Q1 | -4.03 Million USD | -118.05% |
| 2009 FY | - USD | -63.16% |
| 2009 Q3 | -6.33 Million USD | -38.15% |
| 2009 Q2 | -4.58 Million USD | -13.75% |
| 2009 Q4 | -14.36 Million USD | -126.66% |
| 2008 Q3 | -6.67 Million USD | -37.96% |
| 2008 Q2 | -4.84 Million USD | -21.78% |
| 2008 Q1 | -3.97 Million USD | -98.5% |
| 2008 FY | - USD | -109.21% |
| 2008 Q4 | -1.84 Million USD | 72.31% |
| 2007 Q2 | -2.6 Million USD | -40.23% |
| 2007 Q3 | -2.12 Million USD | 18.18% |
| 2007 Q1 | -1.85 Million USD | -116.73% |
| 2007 Q4 | -2 Million USD | 5.94% |
| 2007 FY | - USD | -285.35% |
| 2006 Q1 | -3.29 Million USD | -86.48% |
| 2006 FY | - USD | 154.84% |
| 2006 Q3 | -836.82 Thousand USD | 63.98% |
| 2006 Q4 | 11.09 Million USD | 1425.42% |
| 2006 Q2 | -2.32 Million USD | 29.55% |
| 2005 Q2 | -2.65 Million USD | 6.54% |
| 2005 Q4 | -1.76 Million USD | 8.49% |
| 2005 Q1 | -2.84 Million USD | 32.03% |
| 2005 Q3 | -1.93 Million USD | 27.29% |
| 2005 FY | - USD | 30.53% |
| 2004 Q2 | -2.6 Million USD | -6.32% |
| 2004 Q3 | -2.92 Million USD | -12.44% |
| 2004 Q4 | -4.18 Million USD | -42.88% |
| 2004 FY | - USD | -104.34% |
| 2004 Q1 | -2.44 Million USD | -42.11% |
| 2003 Q1 | -1.22 Million USD | -231.73% |
| 2003 FY | - USD | -60.09% |
| 2003 Q4 | -1.72 Million USD | -21.72% |
| 2003 Q3 | -1.41 Million USD | 11.73% |
| 2003 Q2 | -1.6 Million USD | -24.67% |
| 2002 FY | - USD | -39.0% |
| 2002 Q4 | -387.85 Thousand USD | 50.13% |
| 2002 Q3 | -777.8 Thousand USD | 47.42% |
| 2002 Q2 | -1.47 Million USD | -36.95% |
| 2002 Q1 | -1.08 Million USD | 23.8% |
| 2001 Q1 | -689.04 Thousand USD | 25.32% |
| 2001 Q4 | -1.41 Million USD | -560.62% |
| 2001 FY | - USD | 24.47% |
| 2001 Q3 | 21.45 Thousand USD | 137.29% |
| 2001 Q2 | -825.36 Thousand USD | -19.78% |
| 2000 Q4 | -922.68 Thousand USD | -40.7% |
| 2000 Q1 | -492.34 Thousand USD | 0.0% |
| 2000 FY | - USD | -133.96% |
| 2000 Q3 | -655.76 Thousand USD | 55.43% |
| 2000 Q2 | -1.4 Million USD | -198.84% |
| 1999 FY | - USD | 39.91% |
| 1999 Q2 | -303.04 Thousand USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 64.544% |
| Embecta Corp. | 245.4 Million USD | 55.452% |
| Dynavax Technologies Corporation | 9.66 Million USD | -1030.975% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 172.828% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 32.89% |
| PainReform Ltd. | -9.56 Million USD | 1242.439% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -9148.731% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2958.474% |
| SCYNEXIS, Inc. | 73.47 Million USD | -48.777% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 4749.916% |
| Cosmos Health Inc. | -17.06 Million USD | 740.73% |
| Journey Medical Corporation | 1.92 Million USD | -5590.786% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2958.474% |
| Safety Shot Inc | -12.18 Million USD | 997.155% |
| Alpha Teknova, Inc. | -25.53 Million USD | 528.051% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 168.818% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | -5.088% |
| Theratechnologies Inc. | -10.31 Million USD | 1160.042% |
| Harrow Health, Inc. | 9.72 Million USD | -1024.344% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 2515.912% |
| Biofrontera Inc. | -18.45 Million USD | 692.424% |
| DURECT Corporation | -24.68 Million USD | 542.878% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -11.254% |
| Cronos Group Inc. | -72.14 Million USD | 251.52% |
| OptiNose, Inc. | -15.55 Million USD | 802.887% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 111.82% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 402.977% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -316.201% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -203.405% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 2887.102% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 15478.772% |
| Radius Health, Inc. | 38.31 Million USD | -185.356% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 3500.238% |
| ProPhase Labs, Inc. | -14.82 Million USD | 837.304% |
| Phibro Animal Health Corporation | 84.6 Million USD | -29.209% |
| Procaps Group S.A. | 104.02 Million USD | -5.088% |
| Alvotech | -484.86 Million USD | 122.547% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 1401.274% |
| Viatris Inc. | 3.51 Billion USD | 96.891% |
| Rockwell Medical, Inc. | -4.69 Million USD | 2428.931% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 10902.372% |
| SIGA Technologies, Inc. | 84.15 Million USD | -29.896% |
| Tilray Brands, Inc. | -72.84 Million USD | 250.076% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -13363.054% |
| Shineco, Inc. | -26.55 Million USD | 511.691% |
| PetIQ, Inc. | 81.48 Million USD | -34.158% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 3121.87% |
| Incannex Healthcare Limited | -18.5 Million USD | 690.791% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 73.727% |
| Alimera Sciences, Inc. | 7.27 Million USD | -1402.474% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1389.351% |
| Assertio Holdings, Inc. | -222.44 Million USD | 149.144% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 2839.404% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 2695.521% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 750.559% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 645.76% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 173.308% |
| Hempacco Co., Inc. | -12.77 Million USD | 955.85% |
| Talphera, Inc. | -9.84 Million USD | 1210.75% |
| Alvotech | -484.86 Million USD | 122.547% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | -41.054% |
| Lantheus Holdings, Inc. | 491 Million USD | 77.735% |
| Currenc Group, Inc. | -1.9 Million USD | 5851.947% |
| Kamada Ltd. | 21.53 Million USD | -407.662% |
| Indivior PLC | 66 Million USD | -65.636% |
| Evoke Pharma, Inc. | -7.29 Million USD | 1599.117% |
| Flora Growth Corp. | -45.87 Million USD | 338.326% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 645.76% |
| Evolus, Inc. | -41.81 Million USD | 361.469% |
| HUTCHMED (China) Limited | 25.52 Million USD | -328.236% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 54.726% |
| Akanda Corp. | -27.73 Million USD | 494.149% |